- |||||||||| fluticasone propionate controlled release (EP-104) / Eupraxia Pharma
Trial completion date, Trial primary completion date: A Trial to Evaluate EP-104IAR in Adults With Eosinophilic Esophagitis (EoE). (clinicaltrials.gov) - Aug 14, 2023 P1b, N=24, Recruiting, Responder analyses in subjects with moderate pain demonstrated that clinically meaningful differences persisted for the majority of the study. Trial completion date: Sep 2023 --> Nov 2024 | Trial primary completion date: Sep 2023 --> Nov 2024
- |||||||||| fluticasone propionate controlled release (EP-104IAR) / Eupraxia Pharma, Syreon
PK/PD data, Journal: Pharmacokinetic Profile of Intra-articular Fluticasone Propionate Microparticles in Beagle Dog Knees. (Pubmed Central) - Jan 9, 2020 Highest concentrations of fluticasone propionate in synovial fluid and cartilage generally occurred 5 days postdose in both dose groups and declined with a half-life of approximately 11 to 14 days. Conclusions EP-104IAR is capable of providing a safe and prolonged local exposure to a corticosteroid in the synovial joint while minimizing systemic exposure, with peak exposures occurring within a matter of days after dosing before declining in all tissues in a predictable manner.
- |||||||||| fluticasone propionate controlled release (EP-104IAR) / Eupraxia Pharma, Syreon
Trial completion: STEPUP: Safety Study of a Long-Acting Injectable Steroid to Treat Knee Osteoarthritis (clinicaltrials.gov) - Jan 24, 2018 P1, N=32, Completed, Conclusions EP-104IAR is capable of providing a safe and prolonged local exposure to a corticosteroid in the synovial joint while minimizing systemic exposure, with peak exposures occurring within a matter of days after dosing before declining in all tissues in a predictable manner. Active, not recruiting --> Completed
- |||||||||| fluticasone propionate controlled release (EP-104IAR) / Eupraxia Pharma, Syreon
Enrollment closed, Trial primary completion date: STEPUP: Safety Study of a Long-Acting Injectable Steroid to Treat Knee Osteoarthritis (clinicaltrials.gov) - Mar 21, 2017 P1, N=32, Active, not recruiting, Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2017 --> Dec 2017
|